[Form 4] AMGEN INC Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported routine equity compensation and related tax withholding. On May 5, 2026, he received 12,136 Restricted Stock Units (RSUs) at $0.00 per share and 79,176 non-qualified stock options with a $329.59 exercise price, all granted under Amgen’s Equity Incentive Plan.
The RSUs and options each vest in four equal annual installments of 25% starting on May 5, 2027, with vested RSUs settled in common shares and the options exercisable through May 5, 2036. A separate F-code transaction on May 6, 2026 reflects 1,702 shares used to satisfy tax obligations at $329.59 per share, not an open-market sale. After these transactions, Bradway directly holds 507,239 common shares, in addition to indirect holdings by his spouse and related GRATs.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Bradway Robert A
Role
Chairman, CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 1,702 | $329.59 | $561K |
| Grant/Award | Nqso (Right to Buy) | 79,176 | $329.59 | $26.10M |
| Grant/Award | Common Stock | 12,136 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 507,239 shares (Direct, null);
Nqso (Right to Buy) — 79,176 shares (Direct, null);
Common Stock — 60,060 shares (Indirect, By GRAT)
Footnotes (1)
- The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 1,520 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
Key Figures
RSU grant: 12,136 shares
Option grant size: 79,176 shares
Option exercise price: $329.59 per share
+5 more
8 metrics
RSU grant
12,136 shares
Restricted Stock Units granted on May 5, 2026
Option grant size
79,176 shares
Non-qualified stock options granted on May 5, 2026
Option exercise price
$329.59 per share
Exercise price for non-qualified stock options
Tax-withholding shares
1,702 shares
Shares delivered for tax obligations on May 6, 2026
Direct holdings post-transaction
507,239 shares
Common stock directly held after reported transactions
Indirect spouse holdings
29,940 shares
Common stock held indirectly by spouse
Spousal GRAT holdings
60,060 shares
Common stock held indirectly by Spousal GRAT
GRAT holdings
60,060 shares
Common stock held indirectly by GRAT
Key Terms
Restricted Stock Units (RSUs), Dividend Equivalents (DEs), non-qualified stock options, Equity Incentive Plan, +1 more
5 terms
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Dividend Equivalents (DEs) financial
"These shares include 1,520 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan"
non-qualified stock options financial
"These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan)"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
GRAT financial
"nature_of_ownership": "By GRAT""
FAQ
What equity awards did Amgen (AMGN) CEO Robert Bradway receive in this Form 4?
Robert Bradway received 12,136 Restricted Stock Units and 79,176 non-qualified stock options. Both awards were granted under Amgen’s Equity Incentive Plan and carry no purchase price for the RSUs, while the options have a $329.59 per share exercise price with long-dated terms.
How do the new Amgen (AMGN) RSUs and options granted to the CEO vest?
The RSUs and non-qualified stock options each vest in four equal annual installments of 25% beginning May 5, 2027. Vested RSUs are paid in Amgen common stock, and vested options become exercisable over the same schedule through their May 5, 2036 expiration date.
What are Dividend Equivalents (DEs) mentioned in the Amgen (AMGN) Form 4 footnotes?
Dividend Equivalents are additional credits tied to unvested RSUs, mirroring cash dividends on Amgen stock. In this filing, 1,520 DEs are credited and will be paid in shares on a one-to-one basis according to the RSU vesting schedule, plus cash for any fractional amounts.
What are the key terms of the new Amgen (AMGN) stock options granted to the CEO?
The non-qualified stock options cover 79,176 underlying Amgen common shares at a $329.59 exercise price. They were granted under the Equity Incentive Plan, vest 25% annually starting May 5, 2027, and expire on May 5, 2036 if not exercised before that date.